Evidence map›Paper›PMID 41324667›Full record

ArticleSurgery today2026

Clinical outcomes of adjuvant nivolumab following neoadjuvant chemotherapy and esophagectomy in patients with esophageal cancer: A single-center retrospective cohort study.

Naomichi Koga, Yasue Kimura, Rena Yokomizo, Munehide Terashi, Ayako Iwanaga, Yuta Kasagi, Masahiko Sugiyama, Keishi Sugimachi, Morita Masaru, Mototsugu Shimokawa and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Survival Outcomes of Adjuvant Nivolumab after Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Naomichi KogaDepartment of Gastroenterological Surgery, NHO Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.ORCID http://orcid.org/0000-0002-4260-9936
Yasue KimuraDepartment of Gastroenterological Surgery, NHO Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan. kimura.yasue.740@m.kyushu-u.ac.jp.
Rena YokomizoDepartment of Gastroenterological Surgery, NHO Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.
Munehide TerashiDepartment of Gastroenterological Surgery, NHO Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.
Ayako IwanagaDepartment of Gastroenterological Surgery, NHO Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.
Yuta KasagiDepartment of Gastroenterological Surgery, NHO Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.
Masahiko SugiyamaDepartment of Gastroenterological Surgery, NHO Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.
Keishi SugimachiDepartment of Hepatobiliary-Pancreatic Surgery, NHO Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.
Morita MasaruDepartment of Gastroenterological Surgery, NHO Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.
Mototsugu ShimokawaDepartment of Biostatistics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, 755-8505, Yamaguchi, Japan.
Eiji OkiDepartment of Advanced Medicine and Innovative Technology, Kyushu University Hospital, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe CheckMate 577 trial revealed that adjuvant nivolumab administration following neoadjuvant chemoradiotherapy and surgery significantly improved the disease-free survival (DFS). However, evidence supporting its effectiveness following neoadjuvant chemotherapy and surgery for advanced esophageal cancer remains limited. This study evaluated the efficacy and safety of adjuvant nivolumab therapy in patients receiving neoadjuvant chemotherapy followed by esophagectomy.

methodsWe retrospectively analyzed 53 patients who underwent neoadjuvant chemotherapy followed by esophagectomy for advanced esophageal cancer between 2021 and 2024 years. Patients were divided into the adjuvant nivolumab and non-adjuvant groups. Clinicopathological factors, surgical outcomes, adverse events, and survival rates were compared between the groups. We also investigated the association between immune-related adverse events (irAEs) and survival outcome.

resultsOf the 53 patients, 15 (28%) received adjuvant nivolumab therapy. The DFS was significantly better in the adjuvant nivolumab group. In the multivariate analysis, although not significantly, adjuvant nivolumab was identified as a favorable prognostic factor. In total, 8 patients (53%) developed irAEs; those who developed irAEs and completed 1-year adjuvant nivolumab therapy showed a longer DFS than those without irAEs.

conclusionAdjuvant nivolumab therapy following neoadjuvant chemotherapy and surgery may improve the DFS in patients with advanced esophageal cancer. Appropriate irAE management may support therapy completion and improve patient outcome.

Indexed as

Antineoplastic Agents, ImmunologicalEsophageal NeoplasmsEsophagectomyNeoadjuvant TherapyNivolumabAdultAgedChemotherapy, AdjuvantCohort StudiesCombined Modality TherapyDisease-Free SurvivalFemaleHumansMaleMiddle AgedRetrospective StudiesAntineoplastic Agents, ImmunologicalNivolumabAdjuvant therapyEsophageal cancerImmune checkpoint inhibitorsNivolumab

Identifiers

PMID41324667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.